Lucy A. Young

523 total citations
9 papers, 264 citations indexed

About

Lucy A. Young is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lucy A. Young has authored 9 papers receiving a total of 264 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Oncology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lucy A. Young's work include DNA Repair Mechanisms (6 papers), PARP inhibition in cancer therapy (4 papers) and CRISPR and Genetic Engineering (2 papers). Lucy A. Young is often cited by papers focused on DNA Repair Mechanisms (6 papers), PARP inhibition in cancer therapy (4 papers) and CRISPR and Genetic Engineering (2 papers). Lucy A. Young collaborates with scholars based in United Kingdom, United States and Singapore. Lucy A. Young's co-authors include Zena Wilson, Alan Lau, Antonio Ramos‐Montoya, Gemma N. Jones, Paul W.G. Wijnhoven, Jonathan Stott, Neil H. James, Christophe D. Chabbert, Emma Dean and Giuditta Illuzzi and has published in prestigious journals such as Cancer Research, Oncogene and British Journal of Cancer.

In The Last Decade

Lucy A. Young

9 papers receiving 263 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lucy A. Young United Kingdom	7	204	181	39	26	23	9	264
Leutz Buon United States	10	241 1.2×	133 0.7×	56 1.4×	29 1.1×	44 1.9×	28	368
Michael Peoples United States	9	181 0.9×	105 0.6×	35 0.9×	36 1.4×	59 2.6×	16	267
Manuela Gambella Italy	8	181 0.9×	116 0.6×	61 1.6×	9 0.3×	17 0.7×	13	283
Colin A. Martz United States	4	208 1.0×	83 0.5×	20 0.5×	16 0.6×	46 2.0×	5	294
Jennifer Richmond Australia	7	137 0.7×	101 0.6×	20 0.5×	19 0.7×	33 1.4×	12	334
Valentina Agnusdei Italy	10	205 1.0×	65 0.4×	39 1.0×	19 0.7×	44 1.9×	11	316
Trevor G. Levin United States	6	147 0.7×	189 1.0×	35 0.9×	30 1.2×	74 3.2×	15	314
Jung‐Min Lee United States	8	171 0.8×	123 0.7×	51 1.3×	15 0.6×	60 2.6×	16	277
Y-T Tai United States	7	291 1.4×	74 0.4×	75 1.9×	11 0.4×	21 0.9×	8	367
Poorval Joshi United States	6	219 1.1×	134 0.7×	15 0.4×	33 1.3×	55 2.4×	9	301

Countries citing papers authored by Lucy A. Young

Since Specialization

Citations

This map shows the geographic impact of Lucy A. Young's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lucy A. Young with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lucy A. Young more than expected).

Fields of papers citing papers by Lucy A. Young

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lucy A. Young. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lucy A. Young. The network helps show where Lucy A. Young may publish in the future.

Co-authorship network of co-authors of Lucy A. Young

This figure shows the co-authorship network connecting the top 25 collaborators of Lucy A. Young. A scholar is included among the top collaborators of Lucy A. Young based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lucy A. Young. Lucy A. Young is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Young, Lucy A., Mercedes Vázquez–Chantada, Robert W. Wilkinson, et al.. (2022). Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation. OncoImmunology. 11(1). 23 indexed citations

Wijnhoven, Paul W.G., Antonio Ramos‐Montoya, Zena Wilson, et al.. (2020). Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene. 39(25). 4869–4883. 126 indexed citations

Young, Lucy A., Christelle de Renty, Margaret H. Veldman-Jones, et al.. (2019). Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress. Cancer Research. 79(14). 3762–3775. 54 indexed citations

Floc’h, Nicolas, Susan Ashton, Douglas Ferguson, et al.. (2019). Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma. Molecular Cancer Therapeutics. 18(5). 909–919. 16 indexed citations

Jones, Gemma N., Claire Rooney, Martine P. Roudier, et al.. (2018). pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry. British Journal of Cancer. 119(10). 1233–1243. 28 indexed citations

Wijnhoven, Paul W.G., Christophe D. Chabbert, Jonathan Stott, et al.. (2018). Abstract 337: The PARP inhibitor olaparib is synergistic with the ATR inhibitor AZD6738 in ATM deficient cancer cells. Cancer Research. 78(13_Supplement). 337–337. 6 indexed citations

Young, Lucy A., Oona Delpuech, Brandon S. Willis, et al.. (2018). Abstract LB-263: Preclinical efficacy of the ATR inhibitor AZD6738 in combination with the BTK inhibitor acalabrutinib in ABC-DLBCL models. Cancer Research. 78(13_Supplement). LB–263. 3 indexed citations

Yates, James, Zena Wilson, Lucy A. Young, et al.. (2017). Abstract 2494: ATR inhibitor AZD6738 as monotherapy and in combination with olaparib or chemotherapy: defining pre-clinical dose-schedules and efficacy modelling. Cancer Research. 77(13_Supplement). 2494–2494. 2 indexed citations

Shord, Stacy S., et al.. (2006). Paclitaxel decreases the accumulation of gemcitabine and its metabolites in human leukemia cells and primary cell cultures.. PubMed. 25(6B). 4165–71. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact